Industry News

Biotechnology Industry News

Roche’s investigational KRAS…

July 2nd, 2026|FierceBiotech|

Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial, furthering its ambitions to establish divarasib as a new standard of care.

Merck & Co. has nixed the…

July 1st, 2026|FierceBiotech|

Merck & Co. has nixed the phase 2 study of a potential Alzheimer’s disease medicine after the drug underwhelmed in an interim analysis, marking another blow for the pharma’s struggling partner Neuphoria Therapeutics.

Insilico Medicine has signed a…

July 1st, 2026|FierceBiotech|

Insilico Medicine has signed a deal worth up to $600 million with Japanese Big Pharma Takeda to collaborate on discovery of assets across Takeda’s therapeutic areas of interest.

Ipsen is on a roll this week,…

July 1st, 2026|FierceBiotech|

Ipsen is on a roll this week, scooping up its second biotech in three days in order to firm up its pipeline with promising clinical-stage candidates.

QuantumCell has licensed AlzeCure…

July 1st, 2026|FierceBiotech|

QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease platform and lead asset for $12 million upfront, bagging a potentially symptom-relieving drug candidate that is on the cusp of phase 2.

Coming on the heels of a $130…

June 30th, 2026|FierceBiotech|

Coming on the heels of a $130 million fundraising round just four months ago, bone-focused Angitia Biopharmaceuticals has pivoted away from its lead asset to structure its pipeline around two earlier-stage drug candidates.

Abivax has recovered from a dent…

June 30th, 2026|FierceBiotech|

Abivax has recovered from a dent in its share price after unveiling fresh safety data that appeared to ease investors’ concerns with its ulcerative colitis prospect.

Vistagen’s social anxiety…

June 30th, 2026|FierceBiotech|

Vistagen’s social anxiety disorder drug candidate has flunked another phase 3 trial. But, with a post hoc subpopulation analysis linking fasedienol to a nominally statistically significant improvement, the biotech plans to talk to the FDA

Just two and a half months after…

June 29th, 2026|FierceBiotech|

Just two and a half months after buzzing out of stealth with $300 million and five autoimmune programs from Bristol Myers Squibb, busy Beeline Medicines has flown an extra $126.3 million back to its hive.

After scrapping development on its…

June 29th, 2026|FierceBiotech|

After scrapping development on its diabetic macular edema treatment avoralstat last month, BioCryst has announced it is shuttering all internal discovery programs to focus on external innovation and partnerships.

A phase 2b trial of Evommune’s…

June 29th, 2026|FierceBiotech|

A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint, wiping out a would-be rival to Novartis for the chronic spontaneous urticaria market.

AstraZeneca has shared the data…

June 29th, 2026|FierceBiotech|

AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case for a Strensiq successor tipped to generate blockbuster sales. The company has yet to share data from a

Ipsen is paying $450 million…

June 29th, 2026|FierceBiotech|

Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve Jakafi treatment.

Alopexx has resuscitated its plans…

June 27th, 2026|FierceBiotech|

Alopexx has resuscitated its plans for a public listing as the biotech seeks urgently needed funds to advance a pipeline that includes an infectious disease antibody that was once the focus of a $375 million

Amid a flurry of traditional IPOs…

June 26th, 2026|FierceBiotech|

Amid a flurry of traditional IPOs this spring, Talawar Therapeutics is taking a different path to the public markets via a merger with a special purpose acquisition company.

Epicrispr Biotechnologies has used…

June 26th, 2026|FierceBiotech|

Epicrispr Biotechnologies has used its gene silencing tech to boost muscle mass in three patients with facioscapulohumeral muscular dystrophy, a clinical first for the debilitating disease with no approved treatments.